EvolutionaryScale: Revolutionizing Biology with AI
July 12, 2024, 9:45 pm
EvolutionaryScale
Total raised: $142M
EvolutionaryScale, a cutting-edge AI research lab for biology, has made waves in the scientific community with its groundbreaking ESM3 model. This milestone AI model has the power to generate novel proteins, a feat that would take nature 500 million years to achieve. The company recently secured a staggering $142 million in seed funding, led by industry giants Nat Friedman and Daniel Gross, along with Lux Capital, Amazon, NVentures, and angel investors.
ESM3, the crown jewel of EvolutionaryScale, allows scientists to interactively prompt the creation of proteins, revolutionizing fields like drug discovery, materials science, and carbon capture. The founding team behind ESM3 are trailblazers in the fusion of AI and biology, having developed the first transformer language model for proteins, ESM1. These models have already facilitated groundbreaking research in protein folding and structure determination, empowering scientists worldwide.
Trained with an unprecedented 1 trillion teraflops on a dataset of 2.78 billion proteins, ESM3 is a generative model that can reason over protein sequence, structure, and function simultaneously. This unique capability opens doors to accelerated discovery in various applications, from cancer treatments to carbon capture technologies. By leveraging ESM3, scientists can now understand and create new proteins, essentially making biology programmable.
One of ESM3's most remarkable achievements was the creation of a new Green Fluorescent Protein (GFP) through a chain of thought prompts. This protein, responsible for the glowing colors of jellyfish and coral, is a marvel of nature with its ability to emit light. ESM3's ability to generate such a protein in a fraction of the time it would take through natural evolution showcases the immense potential of AI in biology.
EvolutionaryScale has also collaborated with industry giants like Amazon Web Services (AWS) and NVIDIA to make ESM3 more accessible to researchers worldwide. By providing an open version of ESM3 for non-commercial use and opening an API for closed beta, EvolutionaryScale is democratizing access to cutting-edge AI tools in biology. This partnership with AWS and NVIDIA will further accelerate applications in drug discovery and synthetic biology, benefiting researchers and pharmaceutical companies alike.
In the words of EvolutionaryScale's co-founder and chief scientist, Alexander Rives, "ESM3 takes a step toward a future of biology where AI is a tool to engineer from first principles." The company's vision of using AI to revolutionize biology and empower scientists to create novel solutions is now closer to reality, thanks to the groundbreaking work of EvolutionaryScale and its ESM3 model.
ESM3, the crown jewel of EvolutionaryScale, allows scientists to interactively prompt the creation of proteins, revolutionizing fields like drug discovery, materials science, and carbon capture. The founding team behind ESM3 are trailblazers in the fusion of AI and biology, having developed the first transformer language model for proteins, ESM1. These models have already facilitated groundbreaking research in protein folding and structure determination, empowering scientists worldwide.
Trained with an unprecedented 1 trillion teraflops on a dataset of 2.78 billion proteins, ESM3 is a generative model that can reason over protein sequence, structure, and function simultaneously. This unique capability opens doors to accelerated discovery in various applications, from cancer treatments to carbon capture technologies. By leveraging ESM3, scientists can now understand and create new proteins, essentially making biology programmable.
One of ESM3's most remarkable achievements was the creation of a new Green Fluorescent Protein (GFP) through a chain of thought prompts. This protein, responsible for the glowing colors of jellyfish and coral, is a marvel of nature with its ability to emit light. ESM3's ability to generate such a protein in a fraction of the time it would take through natural evolution showcases the immense potential of AI in biology.
EvolutionaryScale has also collaborated with industry giants like Amazon Web Services (AWS) and NVIDIA to make ESM3 more accessible to researchers worldwide. By providing an open version of ESM3 for non-commercial use and opening an API for closed beta, EvolutionaryScale is democratizing access to cutting-edge AI tools in biology. This partnership with AWS and NVIDIA will further accelerate applications in drug discovery and synthetic biology, benefiting researchers and pharmaceutical companies alike.
In the words of EvolutionaryScale's co-founder and chief scientist, Alexander Rives, "ESM3 takes a step toward a future of biology where AI is a tool to engineer from first principles." The company's vision of using AI to revolutionize biology and empower scientists to create novel solutions is now closer to reality, thanks to the groundbreaking work of EvolutionaryScale and its ESM3 model.